Shares of Nevro Corp. (NYSE:NVRO – Get Rating) have been given an average rating of “Hold” by the eighteen brokerages that are covering the stock, MarketBeat reports. Three research analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $100.54.
A number of brokerages recently weighed in on NVRO. Citigroup upgraded shares of Nevro from a “neutral” rating to a “buy” rating and set a $78.00 price target on the stock in a research report on Thursday, May 5th. Piper Sandler cut their price target on shares of Nevro from $65.00 to $64.00 in a research report on Thursday, May 5th. Bank of America began coverage on shares of Nevro in a report on Wednesday, March 2nd. They set an “underperform” rating on the stock. StockNews.com upgraded shares of Nevro from a “sell” rating to a “hold” rating in a report on Tuesday. Finally, SVB Leerink dropped their target price on shares of Nevro from $105.00 to $85.00 and set an “outperform” rating on the stock in a report on Thursday, February 24th.
Shares of NYSE:NVRO opened at $43.46 on Friday. The company has a market capitalization of $1.53 billion, a price-to-earnings ratio of -11.14 and a beta of 1.07. The firm’s 50 day simple moving average is $66.86 and its 200 day simple moving average is $77.83. The company has a debt-to-equity ratio of 0.77, a current ratio of 6.97 and a quick ratio of 5.32. Nevro has a fifty-two week low of $41.74 and a fifty-two week high of $182.45.
In other news, General Counsel Kashif Rashid bought 1,500 shares of the company’s stock in a transaction dated Friday, March 11th. The stock was bought at an average price of $64.04 per share, with a total value of $96,060.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO D Keith Grossman bought 3,200 shares of the company’s stock in a transaction dated Tuesday, March 8th. The shares were purchased at an average cost of $63.59 per share, with a total value of $203,488.00. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 6,950 shares of company stock valued at $399,673. Company insiders own 2.80% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. Parallel Advisors LLC raised its stake in Nevro by 476.4% in the fourth quarter. Parallel Advisors LLC now owns 317 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 262 shares in the last quarter. Quadrant Capital Group LLC raised its stake in Nevro by 79.5% in the fourth quarter. Quadrant Capital Group LLC now owns 368 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 163 shares in the last quarter. Signaturefd LLC raised its stake in Nevro by 7,028.6% in the fourth quarter. Signaturefd LLC now owns 499 shares of the medical equipment provider’s stock valued at $40,000 after purchasing an additional 492 shares in the last quarter. CWM LLC acquired a new position in Nevro in the fourth quarter valued at about $47,000. Finally, FourThought Financial LLC raised its stake in Nevro by 49.1% in the first quarter. FourThought Financial LLC now owns 683 shares of the medical equipment provider’s stock valued at $49,000 after purchasing an additional 225 shares in the last quarter.
Nevro Company Profile (Get Rating)
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems.
- Get a free copy of the StockNews.com research report on Nevro (NVRO)
- Carvana Insiders Buy Shares But Maybe You Shouldn’t
- Dutch Bros Gets Scalded By Inflation
- The S&P 500 Could Fall Another 28%
- Corning Stock is a Technology Value Play
- Wolverine Worldwide Is Ready To Rebound
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.